Cassiopea (CPPSF) Stock Price, News & Analysis

Company Overview

Cassiopea S.p.A. is an Italian specialty pharmaceutical company focusing on prescription dermatology and medical aesthetics. Headquartered in Milan, Italy, the company was founded in 2000 and trades in the United States over the counter under the symbol CPPSF. Cassiopea’s mission centers on developing and commercializing innovative topical therapies to address unmet needs in skin health.

The company’s lead product is Winlevi (clascoterone cream 1%), an androgen receptor inhibitor approved by the U.S. Food and Drug Administration for the treatment of acne vulgaris. Winlevi represents Cassiopea’s first commercial launch in the United States and is supported by a growing body of clinical data. In addition to Winlevi, the company is advancing a pipeline of topical candidates, including clascoterone formulations for androgenetic alopecia and other dermatological conditions, all designed to leverage the company’s expertise in skin-targeted delivery systems.

Cassiopea operates through its Milan headquarters and maintains a subsidiary presence in the United States to support regulatory, clinical and commercial activities. The company’s management team brings together professionals with deep experience in pharmaceutical R&D, regulatory affairs and global product commercialization. Cassiopea continues to pursue strategic partnerships and licensing opportunities to expand its reach across Europe, North America, and key markets in Asia.

Key Stats

• Today's Range: $35.15 to $35.15
• 50-Day Range: $35.15 to $35.15
• 52-Week Range: $35.15 to $55.81
• Volume: N/A
• Average Volume: 608 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:CPPSF
• CIK: N/A
• Web: www.cassiopea.com
• Phone: (928) 689-1124
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A